[Importance of anthracyclines in infants in the treatment of acute lymphoblastic and non-lymphoblastic leukemias].
Induction treatment of acute non lymphoblastic leukemia in children and in adults must include anthracyclines, but the best anthracycline is still in discussion. In acute lymphoblastic leukemia the use of anthracycline is discussed according to the initial prognostic factors: needful in high risk patients, useless in good risk. In intermediate risk patient, most cooperative protocols include one anthracycline in induction.
D000208:Acute Disease; D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use*; D004317:Doxorubicin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007223:Infant; D007938:Leukemia / Q000188:drug therapy*; D007945:Leukemia, Lymphoid / Q000145:classification / Q000188:drug therapy*; D011241:Prednisone / Q000627:therapeutic use; D012306:Risk; D014750:Vincristine / Q000627:therapeutic use
D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone; D003630:Daunorubicin
Intérêt des anthracyclines chez l'enfant dans le traitement des leucémies aiguës lymphoblastiques et non lymphoblastiques.